Bring the reason you want help, a list of your medicines, and any health records you have. Use these questions to get a clear care plan.
Ask what is being treated, which medicine is meant, and what will be checked. Leave room to ask what the answer means for you.
Tesamorelin (EGRIFTA SV, EGRIFTA WR) is approved to reduce excess belly fat in adults who have HIV and lipodystrophy, as of September 2026.
In the US, the Food and Drug Administration (FDA) handles drug regulation.
HIV is a virus that weakens the body’s ability to fight infections.
Lipodystrophy changes how the body stores fat and can occur with HIV treatment.
As of September 2026, tesamorelin is not approved as a weight-loss medicine.
Prescribing tesamorelin for any other purpose is called off-label use: that purpose has no FDA approval.
This guide cannot confirm whether prescribing for your reason is allowed in your state. Ask the doctor and your state medical board which rules apply.
Ask what studies support that use and what other ways of treating your concern are available.
As of September 2026, EGRIFTA SV and EGRIFTA WR are different versions of tesamorelin; the official medicine information says they cannot be swapped.
Ask which product is meant and which pharmacy would fill it. Get those names in writing.
Peptide means a chain of protein building blocks.
FDA provides a route to each state’s pharmacy-license search.
Find a pharmacy license recordAs of September 2026, the label, the medicine’s official information, calls for blood sugar checks before treatment starts and further checks at intervals during treatment.
The label also calls for tests that measure IGF-1 during treatment; IGF-1 is a body signal that helps cells grow.
Tesamorelin raises IGF-1, and the label says to consider stopping treatment if the level stays too high.
For people with diabetes, it calls for checks for eye damage.
Ask which tests check these levels, where tests happen, and who reads the results. Ask what result would lead the doctor to change or stop treatment.
Ask who arranges an in-person exam if one is needed.
The label says tesamorelin must not be used during pregnancy or by someone with active cancer, as of September 2026.
It also rules out allergy to any ingredient and certain problems with the pituitary gland, which makes body signals.
For someone whose past cancer has been treated and is stable, the label says to weigh possible benefit carefully against the chance of cancer returning.
Bring up your health history and the medicines you take. Ask how each part affects the decision about care.
Researchers followed the same people for longer and saw belly fat return in those switched to a dummy treatment with no tesamorelin.
Ask what change would count as a useful result, when it will be checked, and what happens if treatment ends.
Ask who handles a new concern between visits and how to reach the clinician after your visit.
As of September 2026, medical-board advice says a prescription decision needs more than a form with fixed choices.
This is advice rather than a law; rules are set by each state, as of September 2026.
Ask whether you can exchange follow-up questions with the clinician.
As of September 2026, FDA states that it does not approve health care providers.
Check the clinician’s license with the state board instead.
A tesamorelin product sold for “research,” or mixed with other peptides, is not an approved tesamorelin product, as of September 2026.
Ask for the full product name and have any mismatch explained.